Publication:
Differences in the hepatitis C virus cascade of care and time to initiation of therapy among vulnerable subpopulations using a mobile unit as point-of-care

dc.contributor.authorValencia, Jorge
dc.contributor.authorLazarus, Jeffrey V
dc.contributor.authorCeballos, Francisco C
dc.contributor.authorTroya, Jesús
dc.contributor.authorCuevas, Guillermo
dc.contributor.authorResino, Salvador
dc.contributor.authorTorres-Macho, Juan
dc.contributor.authorRyan, Pablo
dc.contributor.funderGilead Sciences (Spain)
dc.contributor.funderInstituto de Salud Carlos III
dc.contributor.funderAbbVie
dc.contributor.funderAsociación Española para Estudio del Higado (AEEH)es_ES
dc.contributor.funderMadrid Positivo Associationes_ES
dc.date.accessioned2024-05-22T08:54:43Z
dc.date.available2024-05-22T08:54:43Z
dc.date.issued2022-02
dc.description.abstractBackground and aims: People who inject drugs (PWID) and other marginalized populations with high hepatitis C virus (HCV) infection rates represent a unique challenge for treatment initiation due to health, administrative and social barriers. We analysed the HCV cascade of care (CoC) in some vulnerable subpopulations in Madrid, Spain, when using a mobile point-of-care (PoC). Methods: From 2019 to 2021, a mobile unit was used to screen active HCV using a linkage-to-care and two-step PoC-based strategy. Viremic participants were grouped into four subgroups: PWID, homeless individuals and people with a mental health disorder (MHD) and alcohol use disorder (AUD). Logistic regression, and Cox and Aalen's additive models were used to analyse associated factors and differences between groups. Results: A prospectively recruited cohort of 214 HCV-infected individuals (73 PWID, 141 homeless, 57 with a MHD and 91 with AUD) participated in the study. The overall HCV CoC analysis found that 178 (83.1%) attended a hospital, 164 (76.6%) initiated direct-acting antiviral therapy and 141 (65.8%) completed therapy, of which 99 (95.2%) achieved sustained virological response (SVR). PWID were significantly less likely to initiate treatment, whereas individuals with AUD waited longer before starting the treatment. Both people with AUD and PWID were significantly less likely to complete HCV treatment. Conclusions: Overall, SVR was achieved in the majority of the participants treated. However, PWID need better linkage to care and treatment, whereas PWID and AUD need more support for treatment completion.es_ES
dc.description.peerreviewedes_ES
dc.description.sponsorshipThis work was funded by a research grant from Gilead Sciences (CHIME program, IN-ES-987-5391) and Instituto de Salud Carlos III (ISCIII; grant numbers PI20CIII/00004 and RD16CIII/0002/0002 to SR). This work was also funded by AbbVie, Asociación Española para el Estudio del Hígado (AEEH) and Madrid Positivo Association. The funders had no role in the study design, datac ollection, analysis, decision to publish or preparation of the manuscriptes_ES
dc.format.number2es_ES
dc.format.page309-319es_ES
dc.format.volume42es_ES
dc.identifier.citationLiver Int. 2022 Feb;42(2):309-319.es_ES
dc.identifier.doi10.1111/liv.15095es_ES
dc.identifier.e-issn1478-3231es_ES
dc.identifier.journalLiver international : official journal of the International Association for the Study of the Liveres_ES
dc.identifier.pubmedID34767680es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/19519
dc.language.isoenges_ES
dc.publisherWiley
dc.relation.projectFISinfo:fis/Instituto de Salud Carlos III/Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I/Subprograma Estatal de Generación de Conocimiento/PI20-ISCIII Modalidad Proyectos de Investigacion en Salud Intramurales. (2020)/PI20CIII/00004es_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/RD16CIII/0002/0002es_ES
dc.relation.publisherversionhttps://doi.org/10.1111/liv.15095es_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectCascade of carees_ES
dc.subjectHepatitis C viruses_ES
dc.subjectMarginalized populationses_ES
dc.subjectModel of carees_ES
dc.subjectPoint-of-care testes_ES
dc.subject.meshHepatitis Ces_ES
dc.subject.meshHepatitis C, Chronices_ES
dc.subject.meshSubstance Abuse, Intravenouses_ES
dc.subject.meshAntiviral Agentses_ES
dc.subject.meshHepaciviruses_ES
dc.subject.meshHumanses_ES
dc.subject.meshPoint-of-Care Systemses_ES
dc.titleDifferences in the hepatitis C virus cascade of care and time to initiation of therapy among vulnerable subpopulations using a mobile unit as point-of-carees_ES
dc.typeresearch articlees_ES
dc.type.hasVersionSMURes_ES
dspace.entity.typePublication
relation.isAuthorOfPublication8741bd82-84d2-486a-a71c-90cc78f61ed5
relation.isAuthorOfPublication89b17350-14e3-4dfd-b797-6ee6ca5363b8
relation.isAuthorOfPublication.latestForDiscovery8741bd82-84d2-486a-a71c-90cc78f61ed5
relation.isFunderOfPublicatione30731f7-32c2-43af-b658-fe28964bc958
relation.isFunderOfPublication7d739953-4b68-4675-b5bb-387a9ab74b66
relation.isFunderOfPublicationffb8e2d3-a3e4-4345-ade9-736e37d36399
relation.isFunderOfPublication.latestForDiscoverye30731f7-32c2-43af-b658-fe28964bc958
relation.isPublisherOfPublicationd81e762a-95f7-4917-88a1-8004b3b8caa7
relation.isPublisherOfPublication.latestForDiscoveryd81e762a-95f7-4917-88a1-8004b3b8caa7

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
DifferencesHepatitis_C_VirusCascadeCare_2022.pdf
Size:
1.56 MB
Format:
Adobe Portable Document Format
Description: